Novavax shares plunge 65 percent as respiratory vaccine fails in late-stage trial

Novavax Inc shares crashed 65 percent on Thursday after data showed its vaccine failed to prevent RSV disease, a leading cause of respiratory infections in infants, missing the main goal of a late-stage study.

from Reuters: Health News https://ift.tt/2UitLxb
https://ift.tt/xePdMM